BUY Piramal Pharma Limited — IDBI Capital
byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))27 Aug 2026via IDBI Capital Research Calls Telegram
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·28 Aug · 1w ago
Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
NewsGoogle News·26 Aug · 2w ago
3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·26 Aug · 2w ago
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
NewsGoogle News·24 Aug · 2w ago
Yapan Bio to become Piramal subsidiary following acquisition
NewsGoogle News·20 Aug · 2w ago
US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US
NewsGoogle News·27 Aug · 1w ago
US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US
NewsGoogle News·27 Aug · 1w ago
Piramal Pharma emphasises sustainability in FY 2025-26 report
NewsGoogle News·24 Aug · 2w ago
Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore
NewsCnbc-Tv18·13 Aug · 3w ago
MACD below its signal line — bearish momentum
Technicals · macd·6 Sept · today
Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26
NewsGoogle News·24 Aug · 2w ago
Piramal Pharma block deal likely cancelled; stock falls 3%
NewsCnbc-Tv18·14 Aug · 3w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.